Royalty Report: Drugs, Delivery, Biotechnology – Collection: 27091

License Grant

The University hereby grants to Licensee the exclusive right and license in the Territory to practice under the Patent Rights and to make, have made, use, lease, sell and import Licensed Products and to practice the Licensed Processes.   Licensee shall have the right to enter into sublicensing agreements for the rights, privileges and licenses granted hereunder. Certain Patent Rights (as later defined herein) relating to Case No. 6388, Polymerized Liposomes with Enhanced Stability.

License Property

Polymerized Liposomes with Enhanced Stability is a technology that is used for the oral and mucosal delivery of vaccines, allergens, proteins and peptides via Polymerized Liposomes (the Orasome (TM) technology).

Field of Use

This Orasome(TM) technology is based on lipids that can easily be assembled into structures that efficiently capture drugs and proteins, bypassing the destructive action of stomach acids and intestinal degradative enzymes — while being taken up efficiently by crucial key cells in the intestinal tract. Because of the unique ability of these cross-linked liposomes to withstand the cleansing activity of bile salts, digestive enzymes, and gastric acids, this proprietary liposomal technology may be utilized practically and commercially for the oral delivery of many therapeutics.

License Grant

Canadian Licensor hereby grants to Licensee an exclusive license for the Field in the Territory under the Licensed Patents; and an exclusive license for the Field in the Territory under the Know-How; for the sole purpose of developing, making, having made, importing, using, offering for sale and selling Licensed Product in the Territory, including the right to grant sublicenses under these rights as set out in this Agreement.

License Property

Licensed Product means Ciprofloxacin encapsulated in the Licensor Liposome Technology and which is intended for pulmonary delivery.

Ciprofloxacin means the chemical compound known as ciprofloxacin, whose more specified chemical name is 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid and all pharmaceutically active salts thereof.

AERx Device means the durable hand-held device developed by Licensee for the delivery of Ciprofloxacin by inhalation and known as the AERx Device, as such device may be modified pursuant to the Agreement.

Loading Patents means the patents owned by University and exclusively licensed to Licensor and set out in Agreement.
5,800,833 – Method for loading lipid vesicles
5,785,987 – Method for loading lipid vesicles

Sphingosome Patents means the Patents owned by Licensor and set out in this Agreement.
5,543,152 – Sphingosomes for enhanced drug delivery

Licensed Patents means the Loading Patents and the Sphingosome Patents.

Patent means (a) all patent applications filed or having legal force in any country owned or controlled by Licensor as of the Effective Date; (b) all patents that have issued or in the future issue therefrom owned or controlled by Licensor as of the Effective Date, including without limitation utility, model and design patents and certificates of invention; and (c) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions (including supplemental protection certificates), additions, registrations or confirmations to or of any such patent applications and patents.

Licensor Liposome Technology means Licensor’s proprietary liposomal drug delivery system that encapsulates drugs in sphingomyelin/cholesterol liposomes using a proton gradient generated by either an ionophore or methylammonium sulfate.

Field of Use

This agreement pertains to patented liposomal formulation technology for the pulmonary delivery of ciprofloxacin

Ciprofloxacin is a fluoroquinolone (flor-o-KWIN-o-lone) antibiotic that fights bacteria in the body. It is used to treat different types of bacterial infections, including skin infections, bone and joint infections, respiratory or sinus infections, urinary tract infections, and certain types of diarrhea.

License Grant

The Licensor has entered into agreement with the Licensee which is developing several potential products which are vaccine based.

Field of Use

The Licensee wishes to use a combination of liposomes or cochleates in conjunction with Sendai vital proteins and its HIV synthetic peptides to create an EradicAide HIV Vaccine.
The EVP will be used to research and develop such formulation(s) of EradicAide HIV Vaccine to determine feasibility for human clinical trials and eventual marketing.
The Licensee proposes that successful development of EradicAide HIV Vaccine could result in various types of formulations based upon an injectable or oral dosage form
1) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an injectable form
2) HIV synthetic peptides + Sendai Proteins + liposomes or cochleates in an oral form.

To the extent that the Licensee utilizes the Licensor's Bioral drug delivery technology, Bioral Cochleate Technology seeks to use an established, safe nutriceutical, phosphatidyl serine, to nano-encapsulate by means of our patented Cochleate structures, drugs to achieve oral delivery of therapeutic nutriceuticals that normally require injection (such as molecules with poor water solubility, large hydrophilic molecules, and protein and peptide biopharmaceuticals) and to potentially reduce toxicity and side effects frequently associated with established therapeutics.